Coronary heart disease with renal insufficiency
Conditions
Interventions
Spironolactone group:20mg spirolactone
Spironolactone combined with potassium-lowering drug group:20mg spironolactone+5mg Sodium Zirconium Cyclosilicate Powder
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Subjects over 18 years old; 2. Patients with clinical diagnosis of coronary heart disease: the results of coronary angiography showed that the diameter of coronary artery stenosis was more than 50%; 3. Patients with clinical diagnosis of chronic renal insufficiency: the history of renal injury was more than 3 months and glomerular filtration rate was less than 60 ml / min.1.73 m2; 4. Patients with blood potassium >= 3.5mmol/l <= 5.0mmol/l. 5. Patients who signed informed consent.
Exclusion criteria
Exclusion criteria: 1. In patients with liver dysfunction, transaminase was 3 times higher than the upper limit; 2. Patients with EGFR less than 30ml / min .1.73m2 and without renal replacement therapy (hemodialysis, peritoneal dialysis). 3. Patients who need metformin, aminoglycosides, amphotericin B, chemotherapy drugs, non steroidal anti-inflammatory drugs and other drugs for kidney damage during the trial; 4. Patients allergic to contrast medium; 5. Patients with severe cardiac insufficiency NYHA IV, myocardial infarction Killip III-IV, cardiogenic shock, malignant arrhythmia, etc. who need rescue before operation; 6. Patients with abnormal thyroid function; 7. Patients with acute cerebrovascular disease; 8. Patients with malignant tumor; 9. Patients with intraoperative complications; 10. Any situation in which the researcher believes that the patient's condition will hinder the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| aldosterone level;LVEF;LVEDV;type I and III collagen; | — |
Secondary
| Measure | Time frame |
|---|---|
| creatine;eGFR;BNP; | — |
Countries
China
Contacts
Public ContactZhou Hao
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed